Combinostics at AAN
April 2-7, 2022 | Seattle, WA
Will you be attending the 2022 AAN Annual Meeting?
Schedule some time to learn more about how our cNeuro® suite, including the cMRI™ and cDSI™ applications, supports end-to-end management of patients with neurological disorders, from earlier detection to differential diagnosis and monitoring of treatment outcomes.
Using a combination of science and innovative AI technology, we aim to make a difference in the lives of patients with neurological disorders.
Our cNeuro® suite puts the focus on patients by providing clinicians with objective, systematic insights for confident, evidence-based diagnostic and management decisions.
Patient data from multiple sources are integrated and compared with data from previous patients and healthy controls: demographic information, imaging (cMRI) and other biomarkers, clinical characteristics, and neuropsychology tests.
Applications in the cNeuro® suite:
- cDSI
- cMRI
- cPET*
- cARIA*
cDSI
Our AI-driven software tools support early detection, differential diagnosis, prediction of progression, and monitoring of neurodegenerative disorders.
cMRI
cMRI provides fully automated brain MRI quantification for increased throughput, greater objectivity, and high-quality reporting for improved patient care.
